Pasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board

Pasithea Therapeutics Corp. has appointed Dr. James Lee to its scientific advisory board to guide development of PAS-004, a next-generation macrocyclic MEK inhibitor, for ETS2 pathway inflammatory diseases such as inflammatory bowel disease, ulcerative colitis, and ankylosing spondylitis. Dr. Lee's research has identified ETS2 as a central regulator of macrophage-driven inflammation and has shown that MEK inhibitors are the most effective drug class in suppressing ETS2-driven inflammation.

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has appointed Dr. James Lee to its Scientific Advisory Board to guide the development of PAS-004, a next-generation macrocyclic MEK inhibitor. Dr. Lee, a renowned expert from the Francis Crick Institute, will oversee the expansion of PAS-004's applications to treat various ETS2-driven inflammatory diseases, including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis, and ankylosing spondylitis [1].

Dr. Lee's appointment follows his significant 2024 publication in Nature, which identified ETS2 as a key regulator of inflammation in IBD. His research has shown that MEK inhibitors, such as PAS-004, are the most effective drug class in suppressing ETS2-driven inflammation. Dr. Lee brings extensive expertise in IBD research and treatment, having trained at Oxford, Cambridge, and Harvard. He currently serves as a Clinician Scientist Group Leader and Honorary Consultant Gastroenterologist [1].

The appointment aims to expand PAS-004's therapeutic potential beyond its current application for neurofibromatosis type 1 (NF1) to a broader range of inflammatory diseases. Pasithea Therapeutics plans to fund this expansion through non-dilutive financing, including grants and strategic collaborations.

References:

[1] https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-appoints-expert-in-ets2-driven-inflammatory-j8ix3b6czrx4.html